Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Business Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,056 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 17,100 · Balance 14,056 F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectGary Charles Robb TTE Robb Revocable Trust | 39,716 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,716 F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2023 Filed Dec 16, 2023 02:31 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-070903 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 7,700 F1 · kind: These shares were transferred from the custodial account to the child's personal account. F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,700 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,700 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 639 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,700 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 01:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,212 | $27.01 | $167,786.12 |
DisclosureSEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 4 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,390 F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 01:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,381 | $26.27 | $36,277.21 |
DisclosureSEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,602 F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 01:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-23-068650 · ownership.xml · derivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,037 Underlying: Common Stock · 15,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 01:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 8,788 | $26.26 | $230,772.88 |
DisclosureSEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,983 F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on December 4, 2023. The options subject to the net exercise were to expire on February 18, 2025. F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 04, 2023 Filed Dec 7, 2023 01:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 15,000 | $3.29 | $49,350.00 |
DisclosureSEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068330 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,771 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F4 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:23 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 638 | $25.97 | $16,568.86 |
DisclosureSEC source: 0000950170-23-068330 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,133 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: A Form 4 previously filed on September 6, 2023 inadvertently overstated the number of shares held by 501. The number in Column 5 reflects the corrected amount. This error was carried forward in the subsequent Form 4s which were filed on September 18, 2023 and September 20, 2023. F4 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,000 | $32.74 | $163,677.00 |
DisclosureSEC source: 0000950170-23-049039 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,996 F1 · price: Represents the weighted average sale price for entire number of shares sold. The actual sale prices range from $32.72 to $32.79. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 13,963 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-23-048629 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 13,963 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 7,996 | $33.80 | $270,264.80 |
DisclosureSEC source: 0000950170-23-048629 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,996 F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on September 14, 2023. The options subject to the net exercise were to expire on February 18, 2025. F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 22:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 13,963 | $3.29 | $45,938.27 |
DisclosureSEC source: 0000950170-23-048629 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046811 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,029 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 500 | $33.10 | $16,550.00 |
DisclosureSEC source: 0000950170-23-046811 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,529 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 10:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028453 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,029 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,061 F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 7 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,061 F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 8,061 F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 5 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,629 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 4 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,279 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,004 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,729 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,454 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 2,091 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014516 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,179 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 2,091 | $22.97 | $48,030.27 |
DisclosureSEC source: 0000899243-23-014516 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,088 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on June 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 10, 2023 Filed May 11, 2023 23:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 14,000 | $24.07 | $336,980.00 |
DisclosureSEC source: 0000899243-23-012758 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,997 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.99 to $24.16. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 09, 2023 Filed May 11, 2023 23:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 30,000 | $23.87 | $716,100.00 |
DisclosureSEC source: 0000899243-23-012758 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,997 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.81 to $24.04. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,963 Underlying: Common Stock · 60,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 7 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 60,586 | $24.07 | $1,458,305.02 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,997 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on May 5, 2023. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 60,000 | $3.29 | $197,400.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 45,000 | $1.92 | $86,400.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,583 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,600 | $19.86 | $31,776.00 |
DisclosureSEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,983 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 22, 2023 Filed Feb 13, 2024 01:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014085 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,465 F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000950170-23-002950 · ownership.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 11 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 10 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 9 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 186 | $26.03 | $4,841.58 |
DisclosureSEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,143 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 23:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,814 | $26.03 | $125,308.42 |
DisclosureSEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,329 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 21, 2022 Filed Feb 15, 2023 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,383 Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 13,401 | $26.43 | $354,188.43 |
DisclosureSEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,143 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 10,000 | $26.06 | $260,600.00 |
DisclosureSEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,544 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 50,000 | $26.06 | $1,303,000.00 |
DisclosureSEC source: 0000899243-22-030683 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,544 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.72 to $26.39. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,544 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,010 | $25.98 | $26,239.80 |
DisclosureSEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,534 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.